Suppression of memory acquisition following co-administration of lithium and atorvastatin through nitric oxide pathway in mice

Pharmacol Biochem Behav. 2014 Jul:122:203-11. doi: 10.1016/j.pbb.2014.03.023. Epub 2014 Apr 5.

Abstract

Purpose: The aim of this study was to investigate the interactive effect of lithium and atorvastatin on cognitive performance and the role of NO as a potential mechanism involved in this interaction.

Materials and methods: Memory performance was evaluated in a two-trial recognition Y-maze test and a step-through passive avoidance task in mice. Lithium (5, 10, 20 or 40 mg/kg, i.p.) and atorvastatin (1 mg/kg, p.o.) were administered 1 h before each trial, L-NAME, a non-specific NO synthase inhibitor (3, 10 mg/kg, i.p.); aminoguanidine, a specific inducible NO synthase (iNOS) inhibitor (100 mg/kg); and L-arginine, a NO precursor (750 mg/kg) were administered 30 min before training sessions. The level of plasma NO end-products (NOx) was determined using Griess reagent protocol.

Results: 1) Lithium (40 mg/kg) impaired the acquisition of spatial recognition memory; 2) lithium did not affect the retrieval phase of spatial memory; 3) atorvastatin (1 mg/kg) significantly impaired the memory performance, when co-administered with the sub-effective dose of lithium (10 mg/kg), but did not affect the status when administered with lithium (5 mg/kg); 4) L-NAME (10 mg/kg) and aminoguanidine (100 mg/kg) dramatically decreased memory performance in mice received sub-effective doses of both lithium (5 mg/kg) and atorvastatin (1 mg/kg); 5) L-arginine (750 mg/kg) improved the memory acquisition in mice administered lithium (10 mg/kg) and atorvastatin (1 mg/kg); 6) lithium did not affect the cognitive performance in the passive avoidance test. All results were compatible and confirmed with in vitro determination of plasma NOx levels.

Conclusions: Lithium, dose dependently, impaired acquisition phase of spatial recognition memory. Lithium and atorvastatin co-administration impaired spatial recognition memory mediating by nitrergic pathway. In addition to L-arginine, our data from L-NAME and aminoguanidine also support the involvement of NO pathway in this interaction.

Keywords: Atorvastatin; Lithium; Memory; Mice; Nitric oxide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atorvastatin
  • Avoidance Learning / drug effects*
  • Avoidance Learning / physiology
  • Dose-Response Relationship, Drug
  • Heptanoic Acids / administration & dosage*
  • Heptanoic Acids / toxicity
  • Lithium / administration & dosage*
  • Lithium / toxicity
  • Male
  • Memory / drug effects
  • Memory / physiology
  • Memory Disorders / chemically induced*
  • Memory Disorders / metabolism
  • Mice
  • Nitric Oxide / physiology*
  • Pyrroles / administration & dosage*
  • Pyrroles / toxicity
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology

Substances

  • Heptanoic Acids
  • Pyrroles
  • Nitric Oxide
  • Lithium
  • Atorvastatin